Searched for
NOVO NORDISK INDIA
India's GLP-1 boom slows amid price war, weak retentionInitial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...- Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...
- Bombay HC cancels 'Duphachrit' trademark, rules it deceptively similar to Abbott's 'Dupha' familyThe Bombay High Court has cancelled Thane-based Menschlich Healthcare's trademark 'Duphachrit' in favour of Abbott Product Operations AG. T...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- From diapers to drugs: How India's global corporate hubs are putting AI to workHeads of several Global Capability Centres (GCCs) told Reuters they are deploying AI across a host of functions - from marketing and conten...
- India's GCC model shifts from cost to capability as AI, talent strains biteIndia's dominance in global capability centres is evolving. These hubs are now integrated, managing complex functions beyond support. Risin...
- Global firms bring more work in-house at India hubs on AI boostThe shift reflects a structural change in how multinationals use their India operations, moving beyond cost-focused support roles to centre...
- Global firms bring more work in-house at India hubs on AI boostGlobal firms are bringing more work in-house at their India centres. Artificial intelligence is boosting productivity. This reduces relianc...
- Novo Nordisk uses AI to fast-track drug launches, expand India roleNovo Nordisk is leveraging Artificial Intelligence to significantly speed up new drug launches. The company expects to cut down the time to...
- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
- Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarityEli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Stocks in news: SBI, Titan, Hyundai, BSE, Torrent Pharma, Axis BankIndian markets saw volatile trading on Thursday, closing nearly unchanged despite positive signals. Several companies including SBI, Titan,...
- Stocks in news: Paytm, Bajaj Auto, L&T, Bharti Airtel, Hero MotoCorpMarkets closed lower amid global headwinds and geopolitical worries. Several companies like Paytm, Bajaj Auto, and L&T are in focus due to ...
- Emcure eyes India growth, global deals amid strong demandEmcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in I...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Novo Nordisk price cuts set to shake up India’s GLP-1 market, challenge genericsNovo Nordisk is slashing prices for its diabetes and weight loss drugs Ozempic and Wegovy in India. This move aims to make these treatments...
- Novo Nordisk India and Torrent Pharma expand their insulin manufacturing facilityTorrent Pharmaceuticals and Novo Nordisk began their partnership 25 years ago in 1992 with the manufacture and launch of insulin in 40 IU v...
Load More
